Navigation Links
GeneNews Announces First Quarter Results
Date:5/2/2008

------

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(Expressed in Canadian dollars)

Three month period ended March 31

2008 2007

$ $

-------------------------------------------------------------------------

OPERATING ACTIVITIES

Net and comprehensive loss for the period (2,586,310) (1,671,251)

Add items not involving cash

Stock-based compensation 142,274 146,439

Amortization of property, plant and equipment 145,182 84,945

Amortization of intellectual property 110,537 110,537

-------------------------------------------------------------------------

(2,188,316) (1,329,330)

Changes in non-cash operating working capital

Accounts receivable 464,274 (65,871)

Investment tax credits recoverable 464,581 -

Prepaid expenses and deposits (45,869) 74,984

Accounts payable and accrued liabilities (237,571) (2,254)

Deferred revenue (294,286) -

-------------------------------------------------------------------------

Cash used in operating activities (1,837,370) (1,322,471)

-------------------------------------------------------------------------

FINANCING ACTIVITIES

Proceeds from exercise of employee stock options 30,750 25,459

Repayments of long-term debt (142,900) (37,143)

-------------------------------------------------------------------------

Cash provided by (used in) financing activi
'/>"/>

SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
4. GeneNews receives ISO 13485 accreditation
5. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
6. GeneNews announces 2007 year end results
7. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... July 14, 2014 Throughout this ... across the clinical trials space, representing 38 countries ... series entitled “Optimizing Patient Participation in Clinical Trials. ... off with internationally renowned R&D expert, Ken Getz, ... on Reinventing Drug Development through Patient Centricity. , ...
(Date:7/14/2014)... Mass. , July 14, 2014 Minerva ... the development of new therapies to treat neuropsychiatric diseases ... has been appointed vice president of finance and ... Mr. Ahlholm is a senior executive with more than ... at technology and life science companies. His background includes ...
(Date:7/14/2014)... Mateo, CA (PRWEB) July 14, 2014 ... CONNECT patient registry platform, announced that three ... muscular dystrophies; the Phelan-McDermid Syndrome International Registry; ... Nephrotic Syndrome—have been awarded contracts by the ... of the creation of a new health ...
(Date:7/13/2014)... R.I. (Brown University) -- The discovery 30 years ago ... an explosion of nanotechnology research. Now, there appears to ... from Brown University, Shanxi University and Tsinghua University in ... atoms forms a hollow molecular cage similar to a ... boron cage structurepreviously only a matter of speculationdoes indeed ...
Breaking Biology Technology:Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 3
... (the,"Company") (OTC Bulletin Board: TBIO) today announced financial results ... results are,presented in the tables that follow. Second ... of $0.2 million or $0.00 per share,for the second ... of $0.4 million or,$0.01 per share for the second ...
... Mass., Aug. 14 Avitar, Inc. (OTC,Bulletin Board: AVTI) ... ended June 30, 2007. For the quarter ended ... operations compared to $1,202,000 from continuing,operations for the quarter ... amounted to $597,000 versus $696,000. The net income,was $301,000, ...
... -- China Medical,Technologies, Inc. (the "Company") (Nasdaq: ... develops, manufactures and markets advanced in-,vitro diagnostic products ... announced that it will participate in the Morgan,Stanley,s ... Kong Date: August 21, 2007 China ...
Cached Biology Technology:Transgenomic, Inc. Reports Second Quarter 2007 Results 2Transgenomic, Inc. Reports Second Quarter 2007 Results 3Transgenomic, Inc. Reports Second Quarter 2007 Results 4Transgenomic, Inc. Reports Second Quarter 2007 Results 5Transgenomic, Inc. Reports Second Quarter 2007 Results 6Transgenomic, Inc. Reports Second Quarter 2007 Results 7Transgenomic, Inc. Reports Second Quarter 2007 Results 8Avitar Reports Third Quarter Financial Results for Fiscal 2007 2Avitar Reports Third Quarter Financial Results for Fiscal 2007 3Avitar Reports Third Quarter Financial Results for Fiscal 2007 4
(Date:7/14/2014)... have shown how the main psychoactive ingredient in cannabis ... Research published today reveals the existence of previously unknown ... in shrinking tumours. , It is hoped that ... anti-cancer properties. , The research was co-led ... used samples of human breast cancer cells to induce ...
(Date:7/13/2014)... of more effective treatments for cachexia, a profound wasting ... all cancer patients, raising their risk of death, according ... have been tried to reverse the condition, which may ... treatments, but none have had great success. , Scientists ... Nature , led by Bruce Spiegelman, PhD, demonstrated ...
(Date:7/11/2014)... awarded Michael F. Holick, PhD, MD, of Boston University ... Avioli Award. Holick, a professor of medicine, physiology and ... understanding of vitamin D and its role in disease ... the American Society for Bone and Mineral Research (ASBMR) ... It is named for ASBMR,s first president and founding ...
Breaking Biology News(10 mins):UEA research reveals how cannabis compound could slow tumour growth 2Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2
... a drink problem, there is a greater risk that you ... from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. ... 50% more likely to have a drink problem in the ... new light on this link. Carried out by researcher Anna ...
... LAWRENCE University of Kansas scientists have found new evidence ... (LCPUFA) are good for developing brains and hearts. In ... of four formulas from birth to 12 months; three with ... formula with no LCPUFA, and tested at four, six and ...
... our understanding of genetics and biological processes in all animals, ... of animals, scientists are still finding the fruit fly to ... the University of Rochester. The latest revelation has to ... fruit flies. It was widely accepted that all X chromosomes ...
Cached Biology News:New thinking on regulation of sex chromosomes in fruit flies 2
... Serum; U.S. sourced, ideal for ... quality; Low hemoglobin; Endotoxin: < ... of US origin; U.S. sourced, ... an uncompromising quality. Low hemoglobin ...
Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
Fetal Calf Serum Replacement (Bistec) serum...
...
Biology Products: